Skip to main content

Generex Biotech - can the stock add to recent gains?

Starting in November, Generex Biotechnology (GNBT) has been quite volatile. That's about the time the company announced that its Oral-Lyn product had been licensed for commercial use in India. In October, a similar license was obtained in South Africa. The company is in the process of securing approvals to market the product in various Middle Eastern countries, as well.

In mid-November, Wall Street Strategies, an independent stock market research company, published a report on the company. They pointed out that the India news was a distinct positive for GNBT and that the stock is a buy. In addition, their analyst provided a further opinion as follows: "Currently, Oral-lyn is in phase III testing in North America. We expect that approval would automatically make this a $5.00 stock, but once sales begin we think the stock could move even higher." This sounds good but investors should be aware that Generex has retained Wall Street Strategies to provide investor relation services.

Earlier in the year, the stock jumped on a number of news events. There were various patent awards and license agreements in the US and other countries such as Lebanon, Armenia, Georgia, etc. The company began testing of a cancer vaccine in China with early signs of success. Positive analysis from Rodman and Renshaw briefly gave the stock a big boost. GNBT also announced that the number of retail chains in Canada and the United States that are carrying its proprietary Glucose RapidSpray(tm) product has expanded.

Without fail, however, the stock always falls back after a big event. Now, we are approaching an earnings announcement. The stock had over a 7% gain today. What are investors expecting?

Based on the last four quarters, revenues have been minimal and operating earnings negative. Are we actually going to see Generex begin to reap the benefits of some of the recent patents and license agreements? Essentially, GNBT is still a development stage company. Even as Generex gets closer to delivering on the promise of its Oral-Lyn product, it is unlikely that actual profits will be forthcoming this quarter. Investors may need to be prepared to see the stock swoon yet again.

Disclosure: GNBT is in our model portfolio

Comments

Popular posts from this blog

Running TradeRadar on Windows 7 and Windows 8

Development of the original TradeRadar Stock Inspector software was begun back in the days before Windows 7 and Windows 8 were available.

As these newer versions of Windows have become more popular, we have heard from some users that they are having problems installing and running TradeRadar on their newer PCs.

The good news is that TradeRadar will work just fine on Windows 7 and Windows 8. All you have to do is adjust the Windows Compatibility Settings to ensure TradeRadar runs as intended.

It is recommended that you can apply Compatibility Settings when running the initial installation; however, it is also possible to apply Compatibility Settings after the program has been installed.

Prior to installation
After downloading the install program, go to the folder where you have stored the TradeRadarStkInsp_7_Setup.exe or TradeRadarStkInsp_7_PRO_Setup.exe executable. Right-click on the executable file and select Properties. Click the Compatibility tab. Adjust the Compatibility mode to …

Durable Goods report for Sept just so-so but Computer segment is on fire

The Durable Goods advanced report for September 2011 was released on Wednesday.

I like to dig into the Durable Goods report because it can be useful for seeing how tech in aggregate is performing and how the sector may perform in the future. I always focus on two particular measures: shipments and new orders. Let's see how it played out last month.

Shipments -- 

I generally give less importance to Shipments since this is a backward looking measure reflecting orders that have been confirmed, manufactured and shipped. It's similar to earnings reports -- it's good to know but the data is in the past and we're more interested in the future. The following chart shows how September shipments looked for the overall tech sector:


Results for the overall tech sector were a bit weak but take a look at the next chart which tracks the Computers and related products segment:


Results here were actually quite good and, to make things even better, the previous month was revised upward.

N…

Alert HQ has moved!

End of an era!

This site was started way back in 2006/2007 to showcase my blog posts and the Alert HQ buy signals and sell signals. Alert HQ grew to include other kinds of stock alerts including Swing Signals, Trend Busters, Trend Leaders, Cash Flow Kings and more.

In the meantime, I built a sister site, TradingStockAlerts.com and I started using some of the same Alert HQ content over there. As a result, I am discontinuing the Alert HQ data here at Trade-Radar.com

The good news, however, is that all the Alert HQ signals and stock screens are still completely free. In addition, the pages have been enhanced so that you can hover over a stock symbol and a small chart will pop up so you can get a quick look at the stock's recent price action. If you click on a symbol it will take you to a page with plenty of financial and technical analysis information (still free!) as well as a larger chart that you can play with in terms of adding or deleting indicators, moving averages, etc.

Click …